FIGS: A Strong Q2 Quarter, But The 25% Rally Has Already Priced In The 2026 Guidebar

FIGS closed Friday at roughly $14.03, up about 25% from the $10.70 it traded at the start of the week, after reporting second-quarter 2026 results that topped revenue and earnings estimates and raising its full-year outlook. The company grew net revenues 28.8% year-over-year to $196.6 million, delivered $0.15 of diluted EPS against a $0.07 consensus, and lifted its 2026 revenue guidance to approximately 20% growth from a prior range of 14% to 16%. The board also authorized an additional $100 million in share repurchases.

The headline quarter looks impressive. The question is whether a stock that has more than doubled over the past 12 months and just popped a quarter in a single session still has enough runway between business quality and valuation to justify holding — or buying.

The real margins sit below the headline.

Gross margin was reported at 75.2%, up 820 basis points year-over-year. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a proxy for cash earnings before one-time items) reached $36.6 million, or 18.6% of revenue. Those are standout figures for a company whose adjusted EBITDA margin was 11.8% over all of 2025.

But the gross-margin expansion was primarily driven by $7.9 million in IEEPA tariff refunds recognized on goods sold in the prior fiscal year. That is a one-time accounting windfall, not an operating improvement. Strip the refund from adjusted EBITDA and the figure drops to roughly $28.7 million, or about 14.6% of revenue — still solid, but a far less dramatic improvement over the 12.9% run rate from a year ago.

What does matter is the underlying operating leverage. Operating expenses as a percentage of revenue fell to 57.3% from 60.5%, driven by fixed-cost leverage and lower stock-based compensation. That kind of margin expansion from cost discipline is the durable part of the quarter. But it alone doesn't explain a 25% post-earnings jump.

Growth is real, but the next phase gets harder.

Revenue growth of 28.8% is genuine. It came from both more customers and higher monetization. Active customers rose 13.2% to 3.1 million. Revenue per active customer grew 10.1% to $229. Average order value climbed 8.5% to $127. International revenue surged 67%, and non-scrubwear — the company's push beyond its core scrubwear into lab coats, outerwear, and lifestyle products — grew 40.3%.

This is the operating phase that justifies the 20% full-year guidance raise. The business is pulling across more levers.

The problem for the stock is what happens after 2026. Sell-side analysts currently project only 6.1% revenue growth for the 12 months following fiscal 2026, and they expect full-year EPS to shrink from $0.33 to $0.28. That is a sharp deceleration profile. The market has priced the current quarter as the start of a new growth era, but the consensus model doesn't believe in sustained 20% revenue growth.

At roughly $14, with 159 million shares outstanding, FIGS carries a market capitalization around $1.8 billion. That works out to about 2.4 times forward revenue for a company whose growth is expected to decelerate from ~20% in 2026 to low single digits beyond. The trailing P/E sits around 55, which demands continued earnings acceleration to maintain. If 2027 EPS comes in around $0.28 as analysts project, that multiple stretches toward 50 on just 10 cents per quarter of expected run-rate profit.

The catalyst clock and the risk/reward reset.

The 20% revenue guidance for 2026 is the catalyst. If FIGS delivers it and the adjusted EBITDA margin target of 14.8% to 15.0% holds, the deceleration story gets pushed further out. The $200 million buyback program adds a modest amount of share count reduction — maybe 5-7% of the float over time — which supports per-share metrics even if top-line growth moderates.

But at the current price, the stock has already rewarded the guidance raise. The risk/reward is tilted the other way. You're paying 2.4 times sales for a company that analysts expect to grow 6% in the period after 2026, with earnings likely to compress. That multiple is defensible only if management proves this acceleration is durable beyond the current fiscal year, not a one-year surge.

The strongest bear case is that the tariff refund papered over underlying margin pressure, healthcare apparel is a cyclical and competitive niche, and the 28% growth figure was partly a catch-up from last year's softer period. The strongest bull case is that FIGS has genuine brand moat, expanding product categories, and an international runway that can sustain mid-teens growth for years — in which case the sell-side deceleration model is too conservative.

Neither extreme is proven yet. The next two quarters carry the weight.

Hold. The business is improving, the growth trajectory is intact, and the valuation was reasonable at $10. At $14, after absorbing the quarter's best news, the margin for error has narrowed. Wait for the 20% guidance to execute through H2 2026 before adding at this level. If the stock pulls back and the full-year target remains on track, there will be a cleaner entry. But buying into a 25% pop on a quarter padded by a $7.9 million one-time refund isn't the discipline this name now demands.